Li, Jie http://orcid.org/0000-0003-4816-957X
Chin, Christopher R. http://orcid.org/0000-0002-2140-3197
Ying, Hsia-Yuan
Meydan, Cem http://orcid.org/0000-0002-0663-6216
Teater, Matthew R.
Xia, Min
Farinha, Pedro http://orcid.org/0000-0001-9364-9391
Takata, Katsuyoshi
Chu, Chi-Shuen
Jiang, Yiyue http://orcid.org/0000-0001-5488-9763
Eagles, Jenna
Passerini, Verena
Tang, Zhanyun
Rivas, Martin A. http://orcid.org/0000-0002-9603-6897
Weigert, Oliver http://orcid.org/0000-0002-0987-7373
Pugh, Trevor J. http://orcid.org/0000-0002-8073-5888
Chadburn, Amy
Steidl, Christian http://orcid.org/0000-0001-9842-9750
Scott, David W. http://orcid.org/0000-0002-0435-5947
Roeder, Robert G. http://orcid.org/0000-0003-3865-8572
Mason, Christopher E. http://orcid.org/0000-0002-1850-1642
Zappasodi, Roberta http://orcid.org/0000-0002-7031-6671
Béguelin, Wendy http://orcid.org/0000-0002-4894-9229
Melnick, Ari M. http://orcid.org/0000-0002-8074-2287
Funding for this research was provided by:
Leukemia and Lymphoma Society (SCOR 7021-20)
Article History
Received: 18 June 2023
Accepted: 11 March 2024
First Online: 3 April 2024
Competing interests
: A.M.M. has research funding from Janssen, Epizyme and Daiichi Sankyo. A.M.M. has consulted for Exo Therapeutics, Treeline Biosciences, Astra Zeneca, Epizyme. C.S. has performed consultancy for Seattle Genetics, AbbVie, and Bayer and has received research funding from Bristol Myers Squibb, Epizyme and Trillium Therapeutics Inc. D.W.S. has received honoria from Abbvie, AstraZeneca, Incyte and Janssen and research funding from Janssen and Roche. C.E.M. is a cofounder and board member for Biotia and Onegevity Health as well as an advisor or grantee for Abbvie, ArcBio, Daiichi Sankyo, DNA Genotek, Tempus Labs, and Whole Biome. O.W. has research funding from Incyte and serves in the advisory board of BeiGene. T.J.P. has provided consultation for AstraZeneca, Chrysalis Biomedical Advisors, Merck, and SAGA Diagnostics (compensated); and receives research support (institutional) from AstraZeneca and Roche/Genentech. T.J.P. is an inventor on patents of the CapIG-seq and CapTCR-seq methods held by the University Health Network. R.Z. is inventor on patent applications related to work on GITR, PD-1 and CTLA-4. R.Z. is scientific advisory board member of iTEOS Therapeutics, and receives grant support from AstraZeneca and Bristol Myers Squibb. The remaining authors declare no competing interests.